ClinicalTrials.gg

Program

vamorolone

Also written as “Vamorolone”, “Vamorolone 0.25 mg/day/day” and “Vamorolone 0.75 mg/day/day”.

Its studies are mostly in Muscular Dystrophy, Duchenne, led by 2 companies.

Furthest: phase 4, since Apr 28, 201611 company-led studies, 1 open or runningNext primary completion: Sep 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ReveraGen BioPharma70 open or runningphase 2since Apr 28, 2016Mar 2, 2015none ahead
Santhera Pharmaceuticals41 open or runningphase 4since Nov 16, 2024Nov 9, 2021Sep 2028phase 4 · NCT06713135

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2015First study: phase 1 study in HealthyNew to ReveraGen BioPharmaReveraGen BioPharma · NCT02415439 · 86 enrolled · United States
  2. Apr 28, 20162 phase 2 studies in Muscular Dystrophy, DuchenneReveraGen BioPharma · NCT02760277, NCT02760264
  3. Jan 30, 2017Phase 2 study in Muscular Dystrophy, DuchenneReveraGen BioPharma · NCT03038399 · 46 enrolled · United States, Australia, Canada and more
  4. Jan 9, 2018Phase 2 study in Muscular Dystrophy, DuchenneReveraGen BioPharma · NCT03439670 · 121 enrolled · United States, Australia, Belgium and more
  5. Apr 13, 2020Phase 2 study in Pediatric ulcerative colitisReveraGen BioPharma · NCT04348890
  6. Nov 9, 2021Santhera Pharmaceuticals's first study: phase 2 study in Muscular Dystrophy, DuchenneNew to Santhera PharmaceuticalsSanthera Pharmaceuticals · NCT05185622 · 54 enrolled · Canada
  7. Dec 8, 2021Phase 2 study in Muscular Dystrophy, DuchenneReveraGen BioPharma · NCT05166109 · 46 enrolled · United States, Italy
  8. Sep 5, 20242 phase 1 studiesSanthera Pharmaceuticals · NCT06689527, NCT06649409
  9. Nov 16, 2024Phase 4 study in Muscular Dystrophy, DuchenneSanthera Pharmaceuticals · NCT06713135 · 80 enrolled · Belgium, Czechia, Greece and more

Ahead

  1. Sep 2028Primary completion: phase 4 study in Muscular Dystrophy, DuchenneSanthera Pharmaceuticals · NCT06713135

TargetBeta

NR3C1 →NR3C2 →read by rule
“Glucocorticoid receptor agonist; Mineralocorticoid receptor antagonist”ChEMBL 37, by rule

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06713135Muscular Dystrophy, Duchenne · Belgium, Czechia, Greece and more4Active, not recruitingSanthera PharmaceuticalsSep 202880
NCT06689527Drug Interaction · Germany1CompletedSanthera PharmaceuticalsSep 24, 202418
NCT06649409Pharmacodynamic · Germany1CompletedSanthera PharmaceuticalsJun 29, 202430
NCT05166109Muscular Dystrophy, Duchenne · United States, Italy2CompletedReveraGen BioPharmaAug 18, 202546
NCT05185622Muscular Dystrophy, Duchenne · Canada2CompletedSanthera PharmaceuticalsJul 16, 202454
NCT04348890Pediatric ulcerative colitis2WithdrawnReveraGen BioPharmaSep 1, 20220
NCT03439670Muscular Dystrophy, Duchenne · United States, Australia, Belgium and more2CompletedReveraGen BioPharmaFeb 23, 2021121
NCT03038399Muscular Dystrophy, Duchenne · United States, Australia, Canada and more2CompletedReveraGen BioPharmaApr 30, 202046
NCT02760277Muscular Dystrophy, Duchenne · United States, Australia, Canada and more2CompletedReveraGen BioPharmaApr 26, 201848
NCT02760264Muscular Dystrophy, Duchenne · United States, Australia, Canada and more2CompletedReveraGen BioPharmaMay 1, 201848
NCT02415439Healthy · United States1CompletedReveraGen BioPharmaNov 201586

How it is read

Names in the registry

  • “Vamorolone”, 8 entries
  • “Vamorolone 0.25 mg/day/day”, 2 entries
  • “Vamorolone 0.75 mg/day/day”, 2 entries
  • “Vamorolone 2.0 mg/day/day”, 2 entries
  • “Vamorolone 6.0 mg/day/day”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.